Endocrine and Metabolic Effects of Growth Hormone (GH) Compared with GH-Releasing Peptide, Thyrotropin-Releasing Hormone, and Insulin Infusion in a Rabbit Model of Prolonged Critical Illness

Endocrinology

Volumn 145, Issue 1, 2004, Pages 205-213

  Weekers, Frank ^a   Michalaki, Marina ^a   Coopmans, Willy ^a   Van Herck, Eric ^a   Veldhuis, Johannes D ^b   Darras, Veerle M ^a   Van Den Berghe, Greet ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEIODINASE 1; DEIODINASE 3; GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; LIOTHYRONINE; LIVER ENZYME; PRALMORELIN; PROTIRELIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURN; CONTROLLED STUDY; CRITICAL ILLNESS; DOWN REGULATION; ENDOCRINE FUNCTION; ENZYME ACTIVITY; ENZYME ASSAY; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL THERAPY; HORMONE ACTION; HYPERGLYCEMIA; INSULIN INFUSION; INSULIN RESISTANCE; LETHALITY; LIOTHYRONINE BLOOD LEVEL; MALE; METABOLIC REGULATION; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ACUTE DISEASE; ANIMALS; BLOOD GLUCOSE; BURNS; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GROWTH HORMONE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY; LIVER; MALE; OLIGOPEPTIDES; ORGAN SIZE; RABBITS; THYROID GLAND; THYROTROPIN-RELEASING HORMONE;

EID: 0347719517     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1005     Document Type: Article

References (41)

1. Hart D, Wolf S, Herndon D, Chinkes D, Lal S, Obeng M, Beauford R, Mlcak R 2002 Energy expenditure and caloric balance after burn: increased feeding leads to fat rather than lean mass accretion. Ann Surg 235:152-161
2. Takala J, Ruokonen E, Webster N, Nielsen MS, Zandstra DF, Vondelinckx G, Hinds CJ 1999 Increased mortality associated with growth hormone treatment in critically ill adults. N Eng J Med 341:785-792
3. Dahn M, Lange M, Jacobs L 1988 Insulin-like growth factor I production is inhibited in human sepsis. Arch Surg 123:1409-1414
4. Ross RJ 1993 The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill. Intensive Care Med 19:554-557
5. Van den Berghe G 2002 Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 23:370-391
6. Van den Berghe G 2000 Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 143:1-13
7. Weekers F, Van Herck E, Coopmans W, Michalaki M, Bowers CY, Veldhuis JD, Van den Berghe G 2002 A novel in vivo rabbit model of hypercatabolic critical illness reveals a bi-phasic neuroendocrine stress response. Endocrinology 143:764-774
8. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C., Lauwers P, Bouillon R 1996 Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyreotropin-releasing hormone in critical illness. Clin Endocrinol (Oxf) 45:341-351
9. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter R, Veldhuis J, Bowers CY, Bouillon R 1999 Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84:1311-1323
10. Van den Berghe G, Baxter R, Weekers F, Wouters P, Bowers C, Iranmanesh A, Veldhuis J, Bouillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56:655-569
11. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R 2001 Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-1367
12. Verhaeghe J, Suiker AM, Visser WJ, Van-Herck E, Van-Bree R, Bouillon R 1992 The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol 134:485-492
13. Darras V, Visser T, Berghman L, Kuhn E 1992 Ontogeny of type I and III deiodinase activities in embryonic and posthatch chicks: relationship with changes in plasma triiodothyronine and growth hormone levels. Comp Biochem Physiol 103A:131-136
14. Veldhuis JD, Covilson ML, Johnson ML 1987 The pituitary gland secretes in bursts : appraising the nature of glandular secretary impulses by simultanuous multiple parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 84:7686-7690
15. Costa C, Solanes G, Visa J, Bosch F 1998 Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. FASEB J 12:1455-1460
16. Liao W, Rudling M, Angelin B 1995 Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. Eur J Clin Invest 26:254-258
17. Warwick-Davies J, Lowrie D, Cole P 1995 Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis. Infect Immun 63:4312-4316
18. Edwards C, Arkins S, Yunger L, Blum A, Dantzer R, Kelley K 1992 The macrophage activating properties of growth hormone. Cell Mol Neurobiol 12:499-510
19. Jaffe C, Turgeon D, Lown K, Demott-Friberg R, Watkins P 2002 Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol 283:E1008-E1015
20. Roelfsema V, Thomas G, Lin H, Breier B, Maxwell L, Oliver M, Heineman E, Clark R, Gluckman P 2001 the metabolic effects of endotoxin are differentially affected by the pattern of growth hormone administration in the rat. J Endocrinol 171:173-181
21. Shapiro B, Agrawal A, Pampori N1995 gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27:9-20
22. Jeevanandam M, Begay C, Shahbazian L, Petersen S 2000 Altered plasma cytokines and total glutathione levels in parenterally fed critically ill trauma patients with adjuvant recombinant human growth hormone. Crit Care Med 28:324-329
23. Mealy K, Barry M, O'Mahony L, Sheehan S, Burke P, McCormack C, Whitehead A, Bouchier D 1998 Effects of human reconbinant growth hormone on inflammatory responses in patients undergoing abdominal aortic aneurysm repair. Intensive Care Med 24:128-131
24. Rappel M, Hansen M, Diamant M, Pedersen B 1994 In vitro effects of human growth hormone on the proliferative responses and cytokine production of blood mononuclear cells. Horm Metab Res 26:612-614
25. Demling R, Lalonde C 1990 Systemic lipid peroxidation and inflammation induced by thermal injury persists into the post-resuscitation period. J Trauma 30:69-74
26. Van den Berghe G, de Zegher F, Bouillon F1998 Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83: 1827-1834
27. Van den Berghe G, de Zegher F, Baxter R, Veldhuis J, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers C 1998 Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83:309-319
28. Van den Berghe G, de Zegher F, Veldhuis J, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers C1997 The somatotropic axis in critical illness: effect of continuous growth hormone (GH) releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82:590-599
29. Van den Berghe G, de Zegher F, Veldhuis J, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers C1997 The somatotropic axis in critical illness: effect of continuous growth hormone (GH) releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82:590-599
30. Laron Z, Frenkel J, Degenghi R, Anin S, Klinger B, Silbergeld A 1995 Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 43:631-635
31. Copinschi G, Van Onderbergen A, L'Hermite-BaleriauxM, Mendel C, Caufriez A, Leproult R, Bolognese J, De Smet M, Thorner M, Van Cauter E 1996 Effect of a 7 day treatment with a novel, orally active growth hormone secretagogue, MK-677, on 24 hour GH profiles, insulin-like growth factor-I and adrenal cortical function in normal young men. J Clin Endocrinol Metab 81:2776-2782
32. Malmlof K, Bauer M, Johansen P, Ankersen M, Veldhuis J 2002 Daily low-dose GH secretagogue administration stimulates pulsatile GH secretion and elevates plasma IGF-I levels in pigs. Endocrine 16:195-199
33. Bianco A, Salvatore D, Gereben B, Berry M, Larsen P 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
34. Peeters R, Wouters P, Kaptein E, van Toor H, Visser T, Van den Berghe G 2003 Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202-3211
35. Baur A, Baur K, Jarry H, Köhrle J 2000 Effects of proinflammatory cyto-kines on anterior pituitary 5′-deiodinase type I and type II. J Endocrinol 167:505-515
36. Boelen A, Maas M, Lowik C, Platvoet M, Wiersinga W 1996 Induced illness in interleukin-6 knock-out mice: a causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinology 137:5250-5254
37. Darras VM, Berghman LR, Vanderpoorten A, Kühn ER 1992 Growth hormone acutely decreases type III iodothyronine deiodinase in chicken liver. FEBS Lett 310:5-8
38. Vasilatos Y, Zhou Y, Wang X, McMurtry J, Rosebrough R, Decuypere E, Buys N, Darras V, Van der Geyten S, Tomas F 2000 Altered chicken thyroid hormone metabolism with chronic GH enhancement in vivo: consequences for skeletal muscle growth. J Endocrinol 166:609-620
39. Moller J, Jorgensen J, Moller N, Christiansen J, Weeke J 1992 Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism 41:728-731
40. Berry M, Kates A, Larsen P1990 Thyroid hormone regulates type I deiodinase messenger RNA in rat liver. Mol Endocrinol 45:743-748
41. Tabata S, Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Inada M 1999 Effect of triiodothyronine administration on reduced expression of type 1 iodothyronine deiodinase messenger ribonucleic acid in streptozotocin in-duced diabetic rats. Endocr J 46:367-374